Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Nivolumab in Combination With 5-azacytidine in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (BMS Reference CA209-9JY)

NCT03825367 is registered in ClinicalTrials.gov with Therapeutic Advances in Childhood Leukemia Consortium as lead sponsor.

NCT NCT03825367
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03825367 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Nivolumab in Combination With 5-azacytidine in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (BMS Reference CA209-9JY)
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Phase
Phase 1/2
Overall status
Unknown status
Start date
November 29, 2019
Completion date
March 30, 2024
Enrollment
13 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

aml, childhood